Impact of PercuSurge device conjugative with intracoronary administration of nitroprusside on no-reflow phenomenon following primary percutaneous coronary intervention

被引:15
|
作者
Youssef, Ali A.
Wu, Chiung-Jen
Hang, Chi-Ling
Cheng, Cheng-I
Yang, Cheng-Hsu
Chen, Chien-Jen
Chen, Yen-Hsun
Chai, Han-Tan
Chua, Sarah
Yeh, Kuo-Ho
Yip, Hon-Kan
机构
[1] Chang Gung Univ Coll Med, Dept Internal Med, Div Cardiol, Chang Gung Mem Hosp,Kaohsiung Med Ctr, Kaohsiung 83301, Taiwan
[2] Suez Canal Univ Hosp, Dept Cardiol, Ismailia, Egypt
关键词
nitroprusside; no-reflow; PercuSurge device; slow-flow;
D O I
10.1253/circj.70.1538
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The present study tested the hypothesis that when administered in conjunction with a PercuSurge device for treatment of acute myocardial infarction (AMI), intracoronary (IC) administration of nitroprusside (NTP) is safe and superior to IC administration of NTP alone or nitroglycerin (NTG) for reversing slow-flow or no-reflow, both of which occur frequently during primary percutaneous coronary intervention (PCI). Methods and Results Sixty-two patients with ST-segment elevation AMI of < 12h duration undergoing primary PCI were enrolled. When the final Thrombolysis In Myocardial Infarction (TIMI) flow was normal (TIMI-3), NTG 200 mu g was administered first, followed by (5 min later) NTP 100,mu g via an intra-guiding catheter. When final TIMI flow was <= 2, NTG 200 mu g was given, followed by NTP 100 mu g via an export suction catheter advanced into the infract-related artery (IRA). Primary endpoint was epicardial blood flow (TIMI-flow), corrected TIMI frame counts, or microvascular circulation [myocardial blush (MB) grade]. Analytical results indicated that the final TIMI-3 flow was significantly higher in patients receiving NTP than in those receiving NTG therapy (100% vs 88.7%, p=0.023). As compared with NTG, NTP therapy significantly improved final MB grade (p < 0.0001) and corrected TIMI flame count time (p < 0.0001). Subgroup analysis demonstrated that final MB grade (p < 0.001) and corrected TIMI flame count time (p < 0.01) were significantly higher in patients (n=33) with than in patients (n=29) without the PercuSurge. No significant NTP related adverse events occurred, apart from insignificant transient hypotension. Conclusion IC administration of NTP is safe and superior to NTG for improving final epicardial blood flow and microvascular circulation in patients with AMI undergoing primary PCI. Combination therapy of PercuSurge device and NTP provided an additional benefit to NTP alone for improving microvascular circulation.
引用
收藏
页码:1538 / 1542
页数:5
相关论文
共 50 条
  • [21] Microvascular obstruction and the no-reflow phenomenon after percutaneous coronary intervention
    Jaffe, Ronen
    Charron, Thierry
    Puley, Geoffrey
    Dick, Alexander
    Strauss, Bradley H.
    CIRCULATION, 2008, 117 (24) : 3152 - 3156
  • [22] BACK TO THE FUTURE IN TREATMENT OF REFRACTORY NO-REFLOW AFTER PRIMARY PERCUTANEOUS CORONARY INTERVENTION: INTRACORONARY EPINEPHRINE
    Aksu, T.
    Colak, A.
    Kosar, M.
    Sen, T.
    Guray, U.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2011, 147 : S88 - S88
  • [23] BACK TO THE FUTURE IN TREATMENT OF REFRACTORY NO-REFLOW AFTER PRIMARY PERCUTANEOUS CORONARY INTERVENTION: INTRACORONARY EPINEPHRINE
    Aksu, T.
    Colak, A.
    Durukan, M.
    Guray, U.
    Kisacik, H.
    ATHEROSCLEROSIS SUPPLEMENTS, 2011, 12 (01) : 101 - 101
  • [24] Intracoronary epinephrine in the treatment of refractory no-reflow after primary percutaneous coronary intervention: a retrospective study
    Aksu, Tolga
    Guler, Tumer Erdem
    Colak, Ayse
    Baysal, Erkan
    Durukan, Mine
    Sen, Taner
    Guray, Umit
    BMC CARDIOVASCULAR DISORDERS, 2015, 15
  • [25] Intracoronary epinephrine in the treatment of refractory no-reflow after primary percutaneous coronary intervention: a retrospective study
    Tolga Aksu
    Tumer Erdem Guler
    Ayse Colak
    Erkan Baysal
    Mine Durukan
    Taner Sen
    Umit Guray
    BMC Cardiovascular Disorders, 15
  • [26] Does Adjunctive Prophylactic Intracoronary Infusion of Low Dose Alteplase Prevent No-Reflow Phenomenon During Primary Percutaneous Coronary Intervention?
    Hashemi, Mohammad
    Ostovan, Jalal
    Sadeghi, Masoumeh
    Shirvani, Ehsan
    Safaei, Ali
    Sanaei, Shahin
    ARYA ATHEROSCLEROSIS, 2023, 19 (06) : 36 - 43
  • [27] Intracoronary Near- Infrared Spectroscopy to Predict No-Reflow Phenomenon During Percutaneous Coronary Intervention in Acute Coronary Syndrome
    Ozaki, Yuichi
    Kitabata, Hironori
    Takahata, Masahiro
    Hikida, Ryo
    Taruya, Akira
    Wada, Teruaki
    Satogami, Keisuke
    Shiono, Yasutsugu
    Kuroi, Akio
    Yamano, Takashi
    Tanaka, Atsushi
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 84 (18) : B44 - B44
  • [28] META-ANALYSIS OF INTRACORONARY EPINEPHRINE VERSUS CONVENTIONAL THERAPY FOR CORONARY NO-REFLOW PHENOMENON DURING PERCUTANEOUS CORONARY INTERVENTION
    Pusapati, Suma
    Aggarwal, Gaurav
    Palicherla, Anirudh
    Kalathil, Ruth Ann Mathew
    Thandra, Abhishek
    Kanmanthareddy, Arun
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 83 (13) : 921 - 921
  • [29] Intracoronary Near-Infrared Spectroscopy to Predict No-Reflow Phenomenon During Percutaneous Coronary Intervention in Acute Coronary Syndrome
    Ozaki, Yuichi
    Kitabata, Hironori
    Takahata, Masahiro
    Katayama, Yosuke
    Wada, Teruaki
    Hikida, Ryo
    Taruya, Akira
    Shiono, Yasutsugu
    Kuroi, Akio
    Yamano, Takashi
    Tanimoto, Takashi
    Tanaka, Atsushi
    AMERICAN JOURNAL OF CARDIOLOGY, 2024, 219 : 17 - 24
  • [30] Intracoronary nicardipine as a safe and cost-effective alternative to nitroprusside for slow- or no-reflow during percutaneous coronary intervention
    Pennoyer, Adam
    Jennings, Douglas
    Patel, Amisha
    Kirtane, Ajay
    Ma, Karlene
    PHARMACOTHERAPY, 2016, 36 (12): : E213 - E213